Vismodegib-RT Regimen Achieves High Rate of Disease Control in Head and Neck BCC

(MedPage Today) -- More than 90% of patients with locally advanced basal cell carcinoma (BCC) of the head and neck achieved locoregional control (LRC) with vismodegib (Erivedge) and radiation therapy (RT), a small clinical trial showed. LRC at...
Source: MedPage Today Radiology - Category: Radiology Source Type: news